Study of GAT Chemotherapy for Metastatic Breast Cancer
Author Information
Author(s): Passardi Alessandro, Massa Ilaria, Zoli Wainer, Gianni Lorenzo, Milandri Carlo, Zumaglini Federica, Nanni Oriana, Maltoni Roberta, Frassineti Giovanni Luca, Amadori Dino
Primary Institution: Department of Medical Oncology, Morgagni-Pierantoni Hospital, Forlì, Italy
Hypothesis
Can the GAT regimen (gemcitabine, doxorubicin, and paclitaxel) be an effective first-line chemotherapy for metastatic breast cancer?
Conclusion
The GAT regimen is effective in treating anthracycline-naïve metastatic breast cancer and has manageable toxicity.
Supporting Evidence
- The overall response rate was 55.2%, with complete responses in 6.9% and partial responses in 48.3% of patients.
- The median time to progression was 10.2 months and overall survival was 36.4 months.
- Hematological toxicity was the most significant, with grade III-IV neutropenia observed in 69% of patients.
Takeaway
This study tested a new combination of three cancer drugs to see if they work well together for women with advanced breast cancer, and they found it was effective.
Methodology
Patients with stage IIIB-IV breast cancer received a combination of gemcitabine, doxorubicin, and paclitaxel in a phase II trial.
Limitations
The study had a small sample size and was limited to patients who were anthracycline-naïve.
Participant Demographics
Median age was 59 years, with the majority being postmenopausal.
Statistical Information
P-Value
p<0.05
Confidence Interval
95 CI, 37.5% to 62.5%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website